News | January 26, 2022
Cipla’s Q3FY22 PAT at Rs 729 cr.
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
The companies were evaluated via a comprehensive, in-depth assessment process that included a sustainability framework of 300 points each for – Purpose, Partnership, Planet and People
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
It is indicated for the treatment of patients with acromegaly and Gastroenteropancreatic Neuroendocrine Tumours
Clean Max Auriga Power is a special purpose vehicle engaged in the business of production, supply and distribution of solar and wind or other renewable energy generation plant
The company will donate 5000 nebulizers to primary health care centres in rural India
It is India’s first pneumotach based portable wireless Spirometer for diagnosis of Chronic Obstructive Pulmonary Disorder (COPD)
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
Cipla has reported consolidated financial results for the period ended September 30, 2021
Cipla is a leading global pharma company
Subscribe To Our Newsletter & Stay Updated
